TaurelFinance, decoded
Live
Loading market data…
TTaurel

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Investing.com· Reuters· Jul 30, 2026 · 12:00 PM
Regeneron beats quarterly estimates on eczema drug strength, shares rise

This is a summary. Read the complete story at Investing.com below.

Read full article at Investing.com

Related Stories

Deutsche Bank sees cautious positioning despite market resilience
stocksabout 4 hours ago

Deutsche Bank sees cautious positioning despite market resilience

Investing.com

UBS now expects AI capex to reach nearly $1tn this year and around $1.4tn by 2027
stocksabout 7 hours ago

UBS now expects AI capex to reach nearly $1tn this year and around $1.4tn by 2027

Investing.com

US fashion council CEO Kolb resigns after clash with runway show protesters
stocksabout 7 hours ago

US fashion council CEO Kolb resigns after clash with runway show protesters

Investing.com